A team of researchers said on Monday that "no later than 2023" The first vaccine against the human immunodeficiency virus (HIV) will circulate, which will stop "at least 65%" Spreading a pandemic.
The announcement was made at the X Scientific Conference on HIV, which will conclude tomorrow in Mexico City and with the involvement of more than 6,000 experts around the world. According to doctors, the vaccine, which lasted 12 years and was tested in monkeys, would help the immune system to produce anti-virus antibodies.
A human study involving 3800 people, which is expected to start in the coming months in the United States, will be concluded on 23 June 2023.
READ OUT: Explore a massive HIV infection
Participants who will "men who have sex with men" in "transsexuals" the treatments will be administered in approximately 55 clinical research centers in nine countries, including Argentina, with vaccines at four time points for one year and will be randomly selected for the test vaccine or the placebo regime.
"The study will evaluate the efficacy of the vaccine, which showed promising results in previous stages. Until now, previous experiments failed, but the design of this project called Mozaik provides cautious optimism."he said Pedro Cahnthe scientific director of the Huñan Foundation.
Cahn, who participated in an international scientific conference in Mexico, said he was a guest "It is very committed to the initiative." "This can lead to a turning point in the history of the epidemic.", the expert has hoped.
"This can lead to a turning point in the history of the epidemic."
Worldwide, it is estimated that 25 million transgender people with 49 times more risk of living with HIV, while men who have sex with men account for 66% of new infections with this virus in the United States and a large share of new infections in North and South America and in some parts of Europe.
"We are determined to develop an effective HIV vaccine all over the world in order to reduce the way around the estimated 1.5 million new infections each year that occur"he added Larry Coreythe chief researcher of the mosaic study, a virologist and a member of the Faculty of Cancer Research Fred Hutchinson in Seattle, quoted by Efe agency.
READ OUT: Disputed: they are trying to genetically alter the children of mothers with HIV
Specialist warned that the vaccine "This will be another tool that will prevent HIV, but it will not replace other methods."
The study and development of the vaccine is sponsored by a laboratory in the United States, and although it is expected that four years will have clear results on its effectiveness, it is not yet known when it will be available to the general public.
According to the most recent report published by the United Nations, the number of people infected with HIV in Latin America increased by 7% and 2% in Argentina between 2010 and 2018, which is due to the fact that the region is among the countries "viewing areas" in the fight against the virus.